Cancer Treatment Centers of America Purchases BSD-500 Hyperthermia System from BSD Medical

SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) announced today that the Cancer Treatment Centers of America (CTCA) at Western Regional Medical Center, located in the metropolitan Phoenix area, has purchased a BSD-500 Hyperthermia System (BSD-500). CTCA at Western Regional Medical Center is a state-of-the-art cancer facility that provides the most advanced therapeutic resources in cancer treatment in one location ( CTCA is a network of hospitals and one of the premier providers of cancer care in the world. The CTCA hospitals were recently recognized by the Commission on Cancer of the American College of Surgeons as "offering the very best in cancer care." This will be the fourth BSD Hyperthermia system purchased by CTCA, including two systems purchased within the last two months.

“Hyperthermia is a highly specialized cancer treatment modality. When used in combination with external beam radiation therapy, we will be able to optimally treat a cancer with the goal of maximal containment of the disease. By having this treatment available to us, we can offer our patients the best therapeutic options available based on their particular needs,” said Lanceford Chong, MD, Radiation Oncologist at CTCA.

For almost 30 years, CTCA has been on the leading edge of cancer treatment with a personalized, whole-person care model. CTCA physicians provide a full range of treatment options, including options for complex and advanced stage cases, and utilizes innovative new techniques and therapies to fight cancer on all fronts. CTCA is committed to revolutionizing cancer care by providing the most advanced and effective cancer treatments and supportive therapies available in order to treat the cancer and improve the patient’s treatment experience and quality of life.

The BSD-500 Hyperthermia System is used to deliver therapeutic heating (hyperthermia) using either non-invasive (external) hyperthermia, which is delivered using antennas placed over the tumor, or interstitial hyperthermia, which is delivered using antennas that are inserted into the tumor, or a combination of both. The BSD-500 has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the use of hyperthermia in conjunction with radiation therapy to treat certain tumors.

About Cancer Treatment Centers of America®

Founded in 1988, Cancer Treatment Centers of America (CTCA) provides a comprehensive, patient-centered treatment model that fully integrates traditional, state-of-the-art medical treatments with scientifically supported complementary therapies such as nutrition, naturopathic medicine, psychological counseling, physical therapy and spiritual support to meet the special, whole-person needs of advanced stage cancer patients. With a network of cancer treatment hospitals and community oncology programs in Arizona, Illinois, Oklahoma, Pennsylvania and Washington, CTCA encourages patients and their families to participate in treatment decisions with its Patient Empowerment MedicineSM model. For more information about Cancer Treatment Centers of America, go to

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.


BSD Medical Corporation
Dennis Gauger, 801-972-5555
Fax: 801-972-5930
[email protected]

KEYWORDS:   United States  North America  Arizona  Utah

INDUSTRY KEYWORDS:   Surgery  Health  Alternative Medicine  Hospitals  Medical Devices  Oncology  Radiology  Nursing  General Health